PARKINSANG

Parkinson's disease affects more than 12 million people worldwide, and its incidence is on the rise, but it is often diagnosed late and is difficult to diagnose. It often takes years to confirm the diagnosis and distinguish this disease from other similar conditions, which delays treatment and limits its effectiveness.

The technology is based on a novel blood biomarker that uses nuclear magnetic resonance (NMR) to measure a combination of six metabolites. A standardized analytical protocol is combined with a metabolite interpretation algorithm, enabling reliable analysis on existing clinical platforms.

This solution enables early and differential diagnosis with 85% accuracy. It reduces diagnostic delays, improves patient care, and integrates easily into hospital practices thanks to its non-invasive and standardizable approach.

The biomarker is patented and has been validated across multiple cohorts from various geographic regions (the U.S., Italy). The technology is being tested in a hospital setting.

This innovation is designed for the early diagnosis of Parkinson's disease. It can be used in routine hospital settings, at specialized centers, and in clinical MRI facilities to support specialized neurological diagnosis.